While the majority of PCa tumors are adenocarcinomas, which are treatable through Androgen deprivation therapy (ADT or medical castration) and 2nd generation androgen receptor (AR) antagonists [2,3], 10–20% of PCa cases develop castration resistance within 5 years of the initial diagnosis, with this progression typically occurring after 2–3 years of hormonal manipulation [4,5]. The gene discussed is AR; the disease is posterior cortical atrophy.